- Spinal Cord Stimulation (SCS)
- Deep Brain Stimulation (DBS)
- Vagus Nerve Stimulation (VNS)
- Sacral Nerve Stimulation (SNS)
- Percutaneous Electrical Nerve Stimulation (PENS)
- Others
Neurostimulation Devices Market size was valued at USD 5.47 billion in 2022. It is expected to reach USD 10.96 billion in 2029, at a CAGR of 11.8% from 2023-2029. For the treatment of chronic pain, movement problems, epilepsy, and Parkinson's disease, neurostimulation devices administer electrical stimulation to specific regions of the patient's brain, spinal cord, or peripheral nervous system. Spinal cord stimulators, deep brain stimulators, sacral nerve stimulators, vagus nerve stimulators, and cortical stimulators are among the neurostimulation devices. High costs, device malfunctions, and stringent regulatory policies are projected to restrain the growth of the neurostimulation devices market over the forecast period. Furthermore, an increase in the incidence and prevalence of pain and neurological disorders is projected to drive the growth of the neurostimulation devices market. Increases in costs to manage pain conditions are creating a burden on the healthcare system. As per the estimates of the research article published in the Institute of Medicine (IOM) in 2011, the annual healthcare costs due to pain management is at least US$ 560-635 Bn annually in the U.S. In addition, the lack of side effects for the neuromodulation devices are fuelling the growth of the neurostimulation devices market.
Neurostimulation Devices Market Key Developments:
In February 2014, TGA gave hazard alerts to Medtronic's deep brain and spinal cord stimulation systems due to unexpected loss of stimulation and over-stimulation of the devices in Australia.
Neurostimulation Devices Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
11.8%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Neurostimulation Devices Market Dynamics
Rise in adoption of novel devices such as neurostimulation devices in the management of various diseases: pain, neurological disorders, obesity, and sleep apnea, among others over conventional drug treatments are projected to create significant opportunities for the neurostimulation device manufacturers. Currently, few ailments like parkinson's, epilepsy, and urinary incontinence conditions have limited treatment options. Hence, neurostimulation devices became an alternative treatment method to treat aforementioned conditions.
North-America Got Significant Share
Neurostimulation Devices Market Regional Analysis
North America dominates the global neurostimulation devices market in terms of revenue in 2019 owing to active investments by venture capitalists in the neurostimulation device start-ups that are working on novel application areas. For instance, Johnson & Johnson Development Corporation, a venture capital arm of Johnson and Johnson Services Inc., invested in three start-ups that are based out in United States: Nevro Corp., NeuroPace, Inc., and CVRx. Regions such as Asia-Pacific projected to create significant opportunities for neurostimulation devices market in the forecast period owing to increase in adoption of neurostimulation devices.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Neurostimulation Devices Market Segmentation
By Stimulation
By Disease Indication
- Pain
- Neurological Disorders (Includes parkinson's disease, epilepsy, depression, and movement related disorders)
- Sleep Apnea
- Bladder and Bowel dysfunction
- Others
By Charging System
- Rechargeable
- Non- Rechargeable
By End User
- Hospitals
- Specialty Clinics
- Others
Frequently Asked Questions
The neurostimulation devices market is projected to expand at a CAGR of 11.8% during the forecast period
Abbott Laboratories, Axonics Modulation Technologies, BioControl Medica, Bioness Inc, Biowave Corporation
North America is the fastest-growing region for The neurostimulation devices market
| 1.Executive Summary |
| 2.Global Neurostimulation Devices Market Introduction |
| 2.1.Global Neurostimulation Devices Market - Taxonomy |
| 2.2.Global Neurostimulation Devices Market - Definitions |
| 2.2.1. By Stimulation |
| 2.2.2. By Disease Indication |
| 2.2.3. By Charging System |
| 2.2.4. By Region |
| 3.Global Neurostimulation Devices Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Neurostimulation Devices Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Neurostimulation Devices Market By Stimulation, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 5.1. Spinal Cord Stimulation (SCS) |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Deep Brain Stimulation (DBS) |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Vagus Nerve Stimulation (VNS) |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Sacral Nerve Stimulation (SNS) |
| 5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Percutaneous Electrical Nerve Stimulation (PENS) |
| 5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Others |
| 5.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 6.Global Neurostimulation Devices Market By Disease Indication, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 6.1. Pain |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Neurological Disorders (Includes parkinson's disease, epilepsy, depression, and movement related disorders) |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Sleep Apnea |
| 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Bladder and Bowel dysfunction |
| 6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Others |
| 6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 7.Global Neurostimulation Devices Market By Charging System, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 7.1. Rechargeable |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Non- Rechargeable |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 8.Global Neurostimulation Devices Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Neurostimulation Devices Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 9.1. Stimulation Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Spinal Cord Stimulation (SCS) |
| 9.1.2.Deep Brain Stimulation (DBS) |
| 9.1.3.Vagus Nerve Stimulation (VNS) |
| 9.1.4.Sacral Nerve Stimulation (SNS) |
| 9.1.5.Percutaneous Electrical Nerve Stimulation (PENS) |
| 9.1.6.Others |
| 9.2. Disease Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Pain |
| 9.2.2.Neurological Disorders (Includes parkinson's disease, epilepsy, depression, and movement related disorders) |
| 9.2.3.Sleep Apnea |
| 9.2.4.Bladder and Bowel dysfunction |
| 9.2.5.Others |
| 9.3. Charging System Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Rechargeable |
| 9.3.2.Non- Rechargeable |
| 9.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Neurostimulation Devices Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 10.1. Stimulation Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Spinal Cord Stimulation (SCS) |
| 10.1.2.Deep Brain Stimulation (DBS) |
| 10.1.3.Vagus Nerve Stimulation (VNS) |
| 10.1.4.Sacral Nerve Stimulation (SNS) |
| 10.1.5.Percutaneous Electrical Nerve Stimulation (PENS) |
| 10.1.6.Others |
| 10.2. Disease Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Pain |
| 10.2.2.Neurological Disorders (Includes parkinson's disease, epilepsy, depression, and movement related disorders) |
| 10.2.3.Sleep Apnea |
| 10.2.4.Bladder and Bowel dysfunction |
| 10.2.5.Others |
| 10.3. Charging System Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Rechargeable |
| 10.3.2.Non- Rechargeable |
| 10.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 11.Asia Pacific (APAC) Neurostimulation Devices Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 11.1. Stimulation Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Spinal Cord Stimulation (SCS) |
| 11.1.2.Deep Brain Stimulation (DBS) |
| 11.1.3.Vagus Nerve Stimulation (VNS) |
| 11.1.4.Sacral Nerve Stimulation (SNS) |
| 11.1.5.Percutaneous Electrical Nerve Stimulation (PENS) |
| 11.1.6.Others |
| 11.2. Disease Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Pain |
| 11.2.2.Neurological Disorders (Includes parkinson's disease, epilepsy, depression, and movement related disorders) |
| 11.2.3.Sleep Apnea |
| 11.2.4.Bladder and Bowel dysfunction |
| 11.2.5.Others |
| 11.3. Charging System Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Rechargeable |
| 11.3.2.Non- Rechargeable |
| 11.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Neurostimulation Devices Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 12.1. Stimulation Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Spinal Cord Stimulation (SCS) |
| 12.1.2.Deep Brain Stimulation (DBS) |
| 12.1.3.Vagus Nerve Stimulation (VNS) |
| 12.1.4.Sacral Nerve Stimulation (SNS) |
| 12.1.5.Percutaneous Electrical Nerve Stimulation (PENS) |
| 12.1.6.Others |
| 12.2. Disease Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Pain |
| 12.2.2.Neurological Disorders (Includes parkinson's disease, epilepsy, depression, and movement related disorders) |
| 12.2.3.Sleep Apnea |
| 12.2.4.Bladder and Bowel dysfunction |
| 12.2.5.Others |
| 12.3. Charging System Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Rechargeable |
| 12.3.2.Non- Rechargeable |
| 12.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Neurostimulation Devices Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 13.1. Stimulation Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Spinal Cord Stimulation (SCS) |
| 13.1.2.Deep Brain Stimulation (DBS) |
| 13.1.3.Vagus Nerve Stimulation (VNS) |
| 13.1.4.Sacral Nerve Stimulation (SNS) |
| 13.1.5.Percutaneous Electrical Nerve Stimulation (PENS) |
| 13.1.6.Others |
| 13.2. Disease Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Pain |
| 13.2.2.Neurological Disorders (Includes parkinson's disease, epilepsy, depression, and movement related disorders) |
| 13.2.3.Sleep Apnea |
| 13.2.4.Bladder and Bowel dysfunction |
| 13.2.5.Others |
| 13.3. Charging System Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Rechargeable |
| 13.3.2.Non- Rechargeable |
| 13.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Abbott Laboratories (U.S.) |
| 14.2.2.Axonics Modulation Technologies, Inc., (U.S.) |
| 14.2.3.BioControl Medical (U.S.) |
| 14.2.4.Bioness Inc. (U.S.) |
| 14.2.5.Biowave Corporation (U.S.) |
| 14.2.6.Boston Scientific Corporation (U.S.) |
| 14.2.7.Cefaly Technology (Belgium) |
| 14.2.8.Cerbomed GmbH (Germany) |
| 14.2.9.Cogentix Medical (U.S.) |
| 14.2.10.CVRx (U.S.) |
| 14.2.11.Enteromedics Inc. (U.S.) |
| 14.2.12.Imthera (U.S.) |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
- Abbott Laboratories (U.S.)
- Axonics Modulation Technologies, Inc., (U.S.)
- BioControl Medical (U.S.)
- Bioness Inc. (U.S.)
- Biowave Corporation (U.S.)
- Boston Scientific Corporation (U.S.)
- Cefaly Technology (Belgium)
- Cerbomed GmbH (Germany)
- Cogentix Medical (U.S.)
- CVRx (U.S.)
- Enteromedics Inc. (U.S.)
- Imthera (U.S.)
- Inspire Medical Systems Inc., (U.S.)
- LivaNova PLC (U.K.)
- Mainstay Medical International PLC (Republic of Ireland)
- Medtronic (U.S.)
- Neuromod Devices Ltd (Republic of Ireland)
- Neuropace,Inc., (U.S.)
- Nevro Corp (U.S.)
- Novum Therapeutics, Inc. (U.S.)
- Respicardia, Inc. (U.S.)
- ScyFIX (U.S.)
- Soterix Medical Inc (U.S.)
- SPR Therapeutics (U.S.)
- Stimwave LLC (U.S.)
- Synapse Biomedical Inc. (U.S.)
- Brainsway Ltd (Israel)
- MMJ Labs (U.S.)
- Neuronetics (U.S.)
- Neuronix LTD (Israel)